Diabetes

High Fiber Intake Tied to Lower Risk for Noncommunicable Disease

High Fiber Intake Tied to Lower Risk for Noncommunicable Disease

Reduction in risk for range of critical outcomes greatest for daily dietary fiber intake of 25 to 29 g.

No Increased Fracture Risk With Canagliflozin in Type 2 Diabetes

No Increased Fracture Risk With Canagliflozin in Type 2 Diabetes

Rate of the primary outcome was similar for canagliflozin, glucagon-like peptide-1 agonist

Second-Line Antidiabetic Meds May Impact Cardiovascular Risk

Second-Line Antidiabetic Meds May Impact Cardiovascular Risk

Cardiovascular risk increased with sulfonylureas and basal insulin versus newer classes of ADM

Fasting-Evoked Hypoglycemia in Diabetes Is Prevalent

Fasting-Evoked Hypoglycemia in Diabetes Is Prevalent

17.1% of patients reported having experienced one or more events in previous year.

Emotional Stress of Holidays Can Trigger Heart Attacks

Emotional Stress of Holidays Can Trigger Heart Attacks

Higher risk seen on Christmas Eve, particularly in older adults with diabetes, heart disease

ADA 2019 Standards of Care Emphasize Patient-Centered Care

ADA 2019 Standards of Care Emphasize Patient-Centered Care

Updates include use of SGLT-2 inhibitors and GLP-1 receptor agonists for T2DM, CVD; endorsed by ACC

SGLT2 Inhibitors and Urinary Tract Infections: What's the Link?

SGLT2 Inhibitors and Urinary Tract Infections: What's the Link?

For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.

Some With Type 2 Diabetes Inappropriately Monitoring Blood Glucose

Some With Type 2 Diabetes Inappropriately Monitoring Blood Glucose

Median of 2 strips/day used by those taking agents not considered to be risk for causing hypoglycemia

Risk for Hospitalization for Heart Failure Greater With Diabetes

Risk for Hospitalization for Heart Failure Greater With Diabetes

Rate has declined but remains higher in those with type 1 or 2 diabetes than in those without

Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk

Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk

Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.

Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality

Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality

Prediction independent of traditional risk factors such as MetS, glucose, HbA1c in general population

Rotating Night Shift Work, Lifestyle Factors Linked to T2DM

Rotating Night Shift Work, Lifestyle Factors Linked to T2DM

Significant additive interaction identified for night shift work, unhealthy lifestyle for female nurses

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease

Insulin Needed for T2DM Tx Set to Increase >20 Percent by 2030

Insulin Needed for T2DM Tx Set to Increase >20 Percent by 2030

Using higher HbA1c target in over-75s could increase disability-adjusted life-years by 44.2%.

Switching to High-Deductible Insurance Delays Diabetes Care

Switching to High-Deductible Insurance Delays Diabetes Care

Delays in seeking care for first major symptom of macrovascular disease, first major diagnostic test.

SGLT2 Inhibitors May Reduce CV, Renal Risks in Type 2 Diabetes

SGLT2 Inhibitors May Reduce CV, Renal Risks in Type 2 Diabetes

By

SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.

Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM

Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM

Risk increased for lower-limb amputation, diabetic ketoacidosis compared with GLP1 receptor agonists.

AHA: Lasting Benefit for CABG in Diabetes, Multivessel Disease

AHA: Lasting Benefit for CABG in Diabetes, Multivessel Disease

Lower all-cause mortality in CABG group vs PCI-DES group after median follow-up of 7.5 years.

Changes in Risk Indicators of MetS Severity Tied to T2DM Risk

Changes in Risk Indicators of MetS Severity Tied to T2DM Risk

For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM

Treatment resulted in lower HF hospitalization rate in patients with, without atherosclerosis.

Insulins

Insulin products chart with pharmacokinetic properties.

Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease

Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease

Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.

Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk

Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk

Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients

TRT May Reduce Mortality Without Improving CV Health in Diabetes

TRT May Reduce Mortality Without Improving CV Health in Diabetes

By

In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.

Canagliflozin Approved to Reduce Risk of Major Adverse Cardiovascular Events

Canagliflozin Approved to Reduce Risk of Major Adverse Cardiovascular Events

The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.

Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria

Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria

By

Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.

Glucose Dysregulation Seen Years Before Diabetes Diagnosis

Glucose Dysregulation Seen Years Before Diabetes Diagnosis

Fasting plasma glucose, BMI elevated 10 years before diagnosis of prediabetes, diabetes.

Sitagliptin Better for Glycemic Control in T2D With Renal Impairment

Sitagliptin Better for Glycemic Control in T2D With Renal Impairment

Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.

ADA, EASD Issue New Recommendations for T2DM

ADA, EASD Issue New Recommendations for T2DM

Additional focus on lifestyle management, self-management education and support emphasized

Intensive BP Therapy in Diabetes May Lower Risk for CV Events

Intensive BP Therapy in Diabetes May Lower Risk for CV Events

Findings based on data reweighted to reflect the adult population with diabetes in the US.

Sign Up for Free e-newsletters